Fig. 3.
Disease-specific 5-year survival rate (DSS) stratified by immunohistochemical findings of HER2 (a), AR (b) and EGFR (c) in 107 patients. DSS was significantly worse in HER2 or AR positive patients than in HER2 or AR negative patients. However, there was no significant difference of DSS in relation to EGFR expression